(Q38958570)

8 September 2017

title

Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study (English)

1 reference

8 September 2017

0 references

Cutler NR

1

1 reference

8 September 2017

Jhee SS

2

1 reference

8 September 2017

Cyrus P

3

1 reference

8 September 2017

Bieber F

4

1 reference

8 September 2017

TanPiengco P

5

1 reference

8 September 2017

Sramek JJ

6

1 reference

8 September 2017

Gulanski B

7

1 reference

8 September 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

8 September 2017

1 reference

8 September 2017

volume

62

1 reference

8 September 2017

issue

16

1 reference

8 September 2017

page(s)

1433-1441

1 reference

Selective loss of central cholinergic neurons in Alzheimer's disease

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Neocortical cholinergic neurons in elderly people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Presynaptic cholinergic dysfunction in patients with dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Metrifonate. Summary of toxicological and pharmacological information available

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Transformation and action of metrifonate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

A new rating scale for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Safety and tolerability of CI-979 in patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2898%2900082-4

10.1016/S0024-3205(98)00082-4

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference